Study guide
4.4 Substance Use Disorders & Psychopharmacology
USMLE Step 2 CK Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Human Development & Well-Patient Care
1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening
2 Chapter 2: Immune System & Immunologic Disorders
2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles
3 Chapter 3: Blood & Lymphoreticular System
3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders
4 Chapter 4: Behavioral Health & Psychiatric Disorders
4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology
5 Chapter 5: Nervous System & Special Senses
5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies
6 Chapter 6: Musculoskeletal System & Dermatology
6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders
7 Chapter 7: Cardiovascular System
7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease
8 Chapter 8: Respiratory System
8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases
9 Chapter 9: Gastrointestinal System
9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis
10 Chapter 10: Renal, Urinary & Reproductive Systems
10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease
11 Chapter 11: Pregnancy, Childbirth & Puerperium
11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management
12 Chapter 12: Endocrine System
12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology
13 Chapter 13: Multisystem Processes & Critical Care
13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens
14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation
14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine
15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice
15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions
4.4 Substance Use Disorders & Psychopharmacology
Key Takeaways Explain This Topic AI
Alcohol Withdrawal Syndrome progresses from autonomic hyperactivity (6–24 hours) to withdrawal seizures (12–48 hours), alcoholic hallucinosis (12–48 hours with intact sensorium), and Delirium Tremens (48–96 hours; 5% mortality), treated acutely with symptom-triggered benzodiazepines (CIWA-Ar protocol).
Pharmacotherapy for Alcohol Use Disorder includes naltrexone (first-line mu-opioid antagonist; contraindicated in active opioid use or liver failure), acamprosate (NMDA modulator; safe in liver disease, dose-adjusted in renal impairment), and disulfiram (aldehyde dehydrogenase inhibitor).
Opioid overdose presents with the classic triad of respiratory depression, miosis (pinpoint pupils), and central nervous system depression, treated immediately with intravenous or intranasal naloxone.
Lithium toxicity presents with coarse tremor, ataxia, confusion, and nephrogenic diabetes insipidus when serum levels exceed 1.5 mEq/L; hemodialysis is indicated for levels >2.5 mEq/L with severe symptoms or >4.0 mEq/L regardless of symptoms.
Neuroleptic Malignant Syndrome (NMS) presents with hyperthermia, 'lead-pipe' muscle rigidity, autonomic instability, and elevated creatine kinase (CK), requiring drug discontinuation, supportive care, and dantrolene or bromocriptine.
Last updated: July 2026
Pathophysiology & DSM-5 Diagnostic Framework for Substance Use Disorders
Substance use disorders (SUD) are characterized by a cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems. Diagnosis under DSM-5 requires meeting ≥2 of 11 criteria over a 12-month period across four domains: impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal).
Alcohol Use Disorder: Acute Withdrawal & Delirium Tremens Protocol
Alcohol chronic use enhances inhibitory GABA neurotransmission and downregulates NMDA glutamate receptors. Abrupt cessation leads to uninhibited CNS excitation due to GABA hypofunction and NMDA hyperactivation.
Alcohol Withdrawal Timeline & CIWA-Ar Protocol
Mild Autonomic Tremors / Agitation (6–24 hours post-last drink): Tremor, diaphoresis, tachycardia, hypertension, anxiety, insomnia, nausea.
Withdrawal Seizures (12–48 hours): Generalized tonic-clonic seizures, usually single or brief bursts.
Alcoholic Hallucinosis (12–48 hours): Visual, auditory, or tactile hallucinations with intact sensorium and normal vital signs (unlike Delirium Tremens).
Delirium Tremens (DT) (48–96 hours): Life-threatening emergency characterized by delirium (clouded sensorium/disorientation) , severe autonomic instability (fever, severe tachycardia, hypertension), and diaphoresis. Mortality rate is ~5%.
Management involves symptom-triggered benzodiazepines (Diazepam, Chlordiazepoxide) using the CIWA-Ar protocol. In patients with advanced liver dysfunction (cirrhosis), hepatitis, or elderly patients, use short-acting benzodiazepines cleared strictly by glucuronidation without active metabolites: Lorazepam, Oxazepam, Temazepam (LOT) .
Diagnostic & Management Algorithm for Acute Psychotropic Syndromes Diagnostic & Treatment Algorithm for Psychotropic Emergencies:
1. Suspected Hyperthermic / Autonomic Instability Syndrome:
- History of Serotonergic drugs (SSRI, SNRI, MAOI, Tramadol, MDMA) + Hyperreflexia, Inducible Clonus, Tremor, Mydriasis, Bowel hypermotility -> Serotonin Syndrome.
-> Treatment: Discontinue serotonergic agents, supportive care, IV fluids, Benzodiazepines; administer Cyproheptadine if severe.
- History of Antipsychotic exposure + "Lead-pipe" muscle rigidity, Hyporeflexia, Extreme Hyperthermia, Autonomic Instability, Elevated CK -> Neuroleptic Malignant Syndrome (NMS).
-> Treatment: Discontinue antipsychotics, aggressive cooling, IV fluids, ICU monitoring; administer Dantrolene or Bromocriptine.
- History of Anticholinergic exposure (TCAs, Diphenhydramine) + Mydriasis, Anhidrosis ("Dry as a bone"), Flushing ("Red as a beet"), Delirium ("Mad as a hatter"), Urinary retention -> Anticholinergic Toxicity.
-> Treatment: Supportive care, Benzodiazepines for agitation, Physostigmine (central and peripheral cholinesterase inhibitor).
2. Suspected Substance Overdose / Withdrawal:
- Miosis, Respiratory Depression, Hypothermia, Bradycardia -> Opioid Overdose -> Immediate IV/Intranasal Naloxone.
- Tremor, Tachycardia, Hypertension, Agitation, Hallucinosis, Seizures 48-96h post-ingestion -> Delirium Tremens -> High-dose IV Benzodiazepines (Diazepam, Lorazepam).
Maintenance Pharmacotherapy for Substance Use Disorders
Long-term management of substance dependence combines evidence-based pharmacotherapy with psychosocial interventions.
Medication Mechanism of Action Primary Indication Key Contraindications / Monitoring
Naltrexone Mu-opioid receptor antagonist First-line Alcohol Use Disorder & Opioid Use Disorder maintenance Contraindicated in acute hepatitis, liver failure, or active opioid use
Acamprosate Glutamate NMDA receptor modulator Alcohol Use Disorder maintenance (reduces craving) Safe in liver disease; dose-adjust or avoid in severe renal impairment (CrCl <30)
Disulfiram Aldehyde dehydrogenase inhibitor Alcohol Use Disorder (aversion therapy) Causes severe acetaldehyde accumulation if alcohol consumed; requires high motivation
Buprenorphine Partial mu-opioid agonist / kappa antagonist Opioid Use Disorder maintenance Can precipitate withdrawal if administered while full mu-agonists are active
Methadone Long-acting full mu-opioid agonist Opioid Use Disorder maintenance Risk of QTc prolongation, respiratory depression; strictly regulated clinic dispensing
Varenicline Alpha-4 beta-2 nicotinic acetylcholine partial agonist Tobacco Use Disorder cessation Monitor for neuropsychiatric symptoms and vivid dreams; superior efficacy to NRT
Substance Intoxication & Withdrawal Differential
Opioids :
Intoxication : Miosis (pinpoint pupils), CNS depression, respiratory depression, decreased bowel sounds, bradycardia, hypothermia. Reversal: Naloxone .
Withdrawal : Mydriasis (dilated pupils), lacrimation, rhinorrhea, piloerection ("cold turkey"), nausea, abdominal cramping, diarrhea, yawning, muscle aches. Management: Buprenorphine, Methadone, or Clonidine (for autonomic symptoms).
Stimulants (Cocaine, Amphetamines) :
Intoxication : Mydriasis, hypertension, tachycardia, psychomotor agitation, paranoia, chest pain, myocardial infarction, aortic dissection. Management: Benzodiazepines (avoid unopposed alpha-stimulation with pure beta-blockers in acute cocaine chest pain).
Withdrawal : Severe dysphoria, "crash", hypersomnia, hyperphagia, vivid dreams, psychomotor retardation.
Sedatives/Hypnotics (Benzodiazepines, Barbiturates) :
Intoxication : Slurred speech, ataxia, somnolence, respiratory depression (marked when combined with alcohol). Reversal: Flumazenil (competitive GABA antagonist; use with caution due to risk of precipitating withdrawal seizures in chronic users).
Withdrawal : Autonomic hyperactivity, tremor, insomnia, anxiety, generalized seizures (life-threatening).
- Psychotropic Toxicity & Adverse Syndromes
- Serotonin Syndrome vs. Neuroleptic Malignant Syndrome vs. Anticholinergic Toxicity
Recognizing hyperthermic psychiatric emergencies is high-yield for Step 2 CK.
Serotonin Syndrome : Caused by combination or overdose of serotonergic agents (e.g., SSRIs + MAOIs, Linezolid, Tramadol, MDMA). Onset is rapid (<24 hours) . Key physical signs: Hyperreflexia , neuromuscular clonus (spontaneous, inducible, or ocular), tremor, mydriasis, hyperactive bowel sounds, diarrhea, diaphoresis, and fever. Treatment: Discontinue serotonergic drugs, supportive care, IV fluids, benzodiazepines; administer Cyproheptadine (5-HT antagonist) in severe cases.
Neuroleptic Malignant Syndrome (NMS) : Caused by D2 antagonists. Onset is gradual (days to weeks) . Key physical signs: "Lead-pipe" muscle rigidity , hyporeflexia , extreme hyperthermia (>40°C/104°F), autonomic instability, marked elevation of creatine kinase (CK), leukocytosis, and rhabdomyolysis. Treatment: Discontinue antipsychotic, ICU monitoring, aggressive cooling, IV hydration, and Dantrolene (skeletal muscle relaxant) or Bromocriptine / Amantadine (dopamine agonists).
Anticholinergic Toxicity : Caused by TCAs, antihistamines (diphenhydramine), atropine. Features: "Flushed as a beet, dry as a bone, blind as a bat, mad as a hatter, hot as a hare, full as a flask" (mydriasis, anhidrosis, flushing, delirium, hyperthermia, urinary retention, absent bowel sounds). Treatment: Physostigmine .